Menu Search
Equities

Angle PLC

DWV:BER

Angle PLC

Actions
  • Price (EUR)0.114
  • Today's Change-0.003 / -2.56%
  • Shares traded--
  • 1 Year change+7.72%
  • Beta--
Data delayed at least 15 minutes, as of Nov 13 2024 18:27 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

ANGLE plc is a United Kingdom-based liquid biopsy company with circulating tumor cell (CTC) solutions for use in research, drug development and clinical oncology using a simple blood sample. Its circulating tumor cell (CTC) harvesting technology known as the Parsortix PC1 System enables complete downstream analysis of the sample, including whole cell imaging and proteomic analysis and full genomic and transcriptomic molecular analysis. The Parsortix PC1 system is a medical device for the capture and harvest of intact CTCs from metastatic breast cancer (MBC) patient blood for user-validated analysis. Its commercial businesses focus on diagnostic products and clinical services. Its diagnostic products include the Parsortix system and associated consumables. Its services include custom made assay development and clinical trial testing for pharma. The Parsortix technology uses a microfluidic technology in the form of a single use cassette to capture and then harvest CTCs from whole blood.

  • Revenue in GBP (TTM)2.02m
  • Net income in GBP-18.03m
  • Incorporated2003
  • Employees150.00
  • Location
    Angle PLCThe Surrey Research Park, 10 Nugent RoadGUILDFORD GU2 7AFUnited KingdomGBR
  • Phone+44 148 334 3434
  • Fax+44 148 368 5836
  • Websitehttps://www.angleplc.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.